NCT01458392 2022-10-05Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and NeckAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAPhase 2 Completed46 enrolled 16 charts